Ertuğrul Bayram

Çukurova University

H指数:8

被引数:274

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Value of Pretreatment Modified Glasgow Prognostic Score in Nivolumab-Treated Advanced Non-Small Cell Lung Cancer

Nivolumab治疗晚期非小细胞肺癌中治疗前改良格拉斯哥预后评分的预后价值

Journal of Clinical Medicine

IF2.9

2026-10-010

Is There a Tumor Proportion Score Threshold at Which Tumor-Cell PD-L1 Adds Prognostic Information Beyond the International Prognostic Index in Large B-Cell Lymphoma?

是否存在一个肿瘤比例评分阈值，在该阈值下，肿瘤细胞PD-L1能够为大型B细胞淋巴瘤的国际预后指数提供额外的预后信息？

Diagnostics

IF3.3

2026-09-190

EZH2 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Retrospective Cohort Study

EZH2表达及免疫检查点抑制剂治疗非小细胞肺癌患者的临床结局：一项真实世界回顾性队列研究

Journal of Clinical Medicine

IF2.9

2026-09-010

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501)

切除后胆道癌的辅助化疗方案：国家性、比较性、观察性研究（TOG/GI-SAFRADJU-2501）

International Journal of Cancer

IF4.7

2026-08-150

OAAI

Erman Akkus; Mehmet Kayaalp; Müzeyyen Aslı Ergözoğlu; Ilgın Koç Kuş; Doğan Bayram; Bilgeşah Kılıçtaş; Emel Ayvaz Güneyin; Ali Kalem; Haydar Temizyürek; Mehmet Mutlu Çatlı; Mehmet Sinan Akarca; Maral Martin Mıldanoğlu; Görkem Turhan; Mahmut Kara; Hacı Arak; Feyza Arslan Tan; Burak Paçacı; Berkay Yeşilyurt; Orhun Akdoğan; Emine Bihter Çetin; Selahattin Çelik; Fatma Keskin Uzundere; Elif Şahin; Zehra Sadak Öcal; Lamia Şeker Can; Bahadır Köylü; Mehmet Cem Fidan; Esmanur Kaplan Tüzün; Teoman Şakalar; Elif Sertesen Çamöz; Haydar Çağatay Yüksel; Onur Yazdan Balçık; Pınar Peker; Mehmet Yılmaz; Şeymanur Ala Enli; Erdem Kölemen; Sibel Oyucu Orhan; Yakup Düzköprü; Mustafa Ersoy; Tuğba Akın Telli; Mesut Yılmaz; Yusuf İlhan; Atila Yıldırım; Ramazan Coşar; Müslih Ürün; Arif Hakan Önder; Murat Araz; Ertuğrul Bayram; Havva Yeşil Çınkır; Ali Alkan; Mustafa Gürbüz; Nilüfer Avcı; Fatma Paksoy Türköz; İsmail Oğuz Kara; Fatih Köse; İlkay Tuğba Ünek; Ahmet Bilici; Öznur Bal; Şuayib Yalçın; Lorenza Rimassa; Hatime Arzu Yaşar

Clinicopathological Features, Tumor Localization and Treatment Outcomes in Paraganglioma: A Single-Center Medical Oncology Cohort

嗜铬细胞瘤的临床病理特征、肿瘤定位及治疗效果：一项单中心肿瘤内科队列研究

Diagnostics

IF3.3

2026-08-110

Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study

索拉非尼治疗放射性碘难治性分化型甲状腺癌患者的真实世界结果及预后因素：一项多中心研究

Journal of Clinical Medicine

IF2.9

2026-06-240

OAAI

Suheda Atas Ipek; Sendag Yaslikaya; Ismail Oguz Kara; Tolga Koseci; Ertugrul Bayram; Esra Asarkaya; Hatice Asoglu; Mehmet Turker; Abdurrahman Aykut; Seda Jeral Evinc; Ozkan Alan; Mehmet Emin Yilmaz; Ozturk Ates; Hatime Arzu Yasar; Mehmet Kayaalp; Esra Asik; Atila Yildirim; Burcu Bacak; Meltem Baykara; Dicle Yurdatap Koc; Muhammed Bekir Hacioglu; Suleyman Alkan; Ferhat Ekinci; Ahmet Burak Agaoglu; Mesut Yilmaz; Ilhan Hacibekiroglu; Mustafa Karaca; Taliha Guclu Kantar; Gamze Gokoz Dogu; Tuba Karacelik; Melek Karakurt Eryilmaz; Teoman Sakalar; Sedat Biter; Mehmet Mutlu Kıdı; Yasemin Aydınalp Camadan; Mahmut Buyuksimsek

Efficacy and Tolerability of Pazopanib in Elderly Patients with Advanced Soft Tissue Sarcoma: A Multicentre Real-World Study from Turkey

帕唑帕尼在老年晚期软组织肉瘤患者中的疗效和耐受性：来自土耳其的多中心真实世界研究

Journal of Clinical Medicine

IF2.9

2026-06-230

Feasibility and Concordance of a Large Language Model (ChatGPT-5) as a Clinical Decision Support Tool in Gynecologic Oncology Tumor Boards: A Blinded, Multi-Observer Study

大型语言模型（ChatGPT-5）作为妇科肿瘤学肿瘤委员会临床决策支持工具的可行性与一致性：一项盲法、多观察者研究

Journal of Clinical Medicine

IF2.9

2026-06-090

Impact of Anatomical Localization on Systemic Inflammatory Markers and Immune Checkpoint CD47 in Desmoid Tumors

解剖学定位对侵袭性纤维瘤病系统性炎症标志物和免疫检查点CD47的影响

Journal of Clinical Medicine

IF2.9

2026-05-240

Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

基线维生素D状态及接受纳武利尤单抗治疗的晚期非小细胞肺癌患者的临床结局

Scientific Reports

IF3.9

2026-04-140

OAAI

Gözde Ağdaş; Duygu Bayir; Elif Şahin; Muhammet Cengiz; Deniz Can Güven; Mehmet Salim Demir; Ertuğrul Bayram; Duygu Özaşkın; Meltem Baykara; Oktay Bozkurt; Mevlüde İnanç; Metin Özkan; Ayşe Nuransoy Cengiz; Mustafa Erman; Umut Kefeli; Emel Mutlu Özkan; Erkam Kocaaslan; Devrim Çabuk; Saadettin Kiliçkap; Pervin Can Sanci; Muslih Urun; Teoman Sakalar; Cengiz Akosman; Erdem Kolemen; Ezgi Turkoğlu; Anıl Karakayali; Mustafa Ersoy; Sedat Yildirim; Latif Karahan; Hayati Arvas; Mehmet Mutlu Kidi; Sedat Biter; Berrak Mermit Ercek; Nargiz Majidova; Havva Yesil Cinkir; Aslihan Ezgi Apaydin Rollas; İbrahim Karadağ

The Correlation Between PD-L1 Expression in Metaplastic Breast Cancer and Clinical-Pathological Features and Prognosis

间变性乳腺癌中PD-L1表达与临床病理特征及预后的相关性

Medicina-Lithuania

IF2.4

2026-04-100

Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

曲妥珠单抗德鲁替康在HER2+转移性乳腺癌患者中的真实世界疗效：土耳其肿瘤学组多中心研究

Therapeutic Advances in Medical Oncology

IF4.2

2026-03-130

PRE

Taha Koray Sahin; Fatih Kemik; Harun Muglu; Bedriye Acikgöz Yildiz; Sedat Biter; Salih Tunbekici; Ahmet Oruc; Ali Kaan Guren; Kerim Kaban; Halil Goksel Guzel; Cihan Erol; Musa Baris Aykan; Bahadir Koylu; Omer Burak Ekinci; Ilknur Deliktas Onur; Ali Kalem; Oguz Altunok; Mustafa Seyyar; Bunyamin Guney; Orhun Akdogan; Rashad Ismayilov; Fadime Sinem Ardic; Melike Yazici; Nargiz Majidova; Sema Turker; Ece Esin; Devrim Cabuk; Hatime Arzu Yasar; Arzu Oguz; Ozan Yazici; Riza Umar Gursu; Mesut Yılmaz; Havva Yesil Cinkir; Ozturk Ates; Emir Celik; Nuri Karadurmus; Umut Demirci; Banu Ozturk; Nil Molinas Mandel; Ibrahim Vedat Bayoglu; Murat Araz; Erdem Goker; Ertugrul Bayram; Dilek Erdem; Fatih Selcukbiricik; Gul Basaran; Ahmet Sezer; Gamze Gokoz Dogu; Yasemin Kemal; Ahmet Bilici; Seyda Gunduz; Deniz Can Guven; Sercan Aksoy

Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

卵巢癌一线PARP抑制剂治疗的结局：一项多中心回顾性分析

Journal of Clinical Medicine

IF2.9

2026-02-220

OAAI

Koksal, Baris; Yildirim, Hasan Cagri; Guven, Deniz Can; Kose, Fatih; Koymen, Gorkem; Ozdemir, Ozlem; Ozberk, Ugur; Algin, Efnan; Guliyev, Murad; Demirci, Nebi Serkan; Alan, Ozkan; Baklaci, Ahmet; Demir, Bilgin; Topkaya, Ozlem; Uskent, Necdet; Yucel, Kadriye Bir; Akdogan, Orhun; Koylu, Bahadir; Selcukbiricik, Fatih; Bilgetekin, Irem; Helvaci, Kaan; Unal, Ahmet; Semiz, Huseyin Salih; Sakalar, Teoman; Sever, Nadiye; Cicek, Ceren Mordag; Dogu, Gamze Gokoz; Biter, Sedat; Bayram, Ertugrul; Yildiz, Canan; Demir, Hacer; Bayrakci, Ismail; Erdogan, Bulent; Kalender, Mehmet Emin; Guzel, Halil Goksel; Ozturk, Banu; Karabuga, Berkan; Ates, Ozturk; Cetin, Emine Bihter; Sahbazlar, Mustafa; Inal, Ali; Sunar, Veli; Basal, Fatma Bugdayci; Asik, Esra; Yildirim, Atila; Oksuz, Nejat Emre; Urun, Yuksel; Nayir, Erdinc; Turker, Sema; On, Sercan; Aytac, Ali; Menekse, Serkan; Temi, Yasemin Bakkal; Uygun, Kazim; Sahin, Elif; Keskinkilic, Merve; Arik, Zafer

Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study

基线葡萄糖与淋巴细胞比值预测晚期非小细胞肺癌患者纳武利尤单抗疗效：一项多中心回顾性研究

Frontiers in Immunology

IF5.9

2026-02-120

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

brigatinib 在晚期ALK阳性NSCLC中的真实世界有效性与安全性：土耳其肿瘤学组进行的一项全国多中心研究

Clinical and Translational Oncology

IF2.5

2026-02-110

PRE

Salih Tunbekici; Hamit Bal; Oguzcan Kınıkoglu; Hayati Arvas; Harun Muglu; Ahmet Bilici; Mustafa Seyyar; Halil Goksel Guzel; Banu Ozturk; Ozge Yalıcı; Duygu Ozaskın; Ramazan Cosar; Fatmagul Cıkladılmez; Evrican Zin; Aytac Terzi; Tugce Ulaslı; Taha Koray Sahın; Denız Can Guven; Gamze Serın; Merve Bıyıklı Alemdar; Bilgin Demir; Ali Kalem; Pervin Can; Kazım Uygun; Elif Sahin; Teoman Sakalar; Ali Kaan Guren; Gokhan Ozturk; Enes Yesılbas; Tugce Kubra Gunes; Burcu Belen; Muzaffer Ugraklı; Kursat Dıslı; Ahmet Oruc; Melek Karakurt Eryılmaz; Ismet Culcuoglu; Mustafa Ersoy; Bahadır Koylu; Fatih Selcukbiricik; Oguzhan Yıldız; Mehmet Emın Yılmaz; Saadettin Kılıckap; Ertugrul Bayram; Caner Acar; Gokhan Sahin; Haydar Cagatay Yuksel; Mustafa Murat Mıdık; Pınar Gursoy; Erdem Goker

Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG)

葡萄膜黑色素瘤的真实治疗模式和生存率: 土耳其肿瘤学组 (TOG) 的一项多中心队列研究

Cancers

IF4.4

2026-01-280

Sercan On; Selin Cebeci; Zeynep Hande Turna; Zeynep Gülsüm Güç Sevgen; Deniz Can Guven; Sadettin Kılıçkap; Mehmet Nuri Başer; Bilgin Demir; Sedat Biter; Ertuğrul Bayram; Berkay Yeşilyurt; Doğan Uncu; Ahmet Melih Arslan; Elif Atağ Akyürek; Hayati Arvas; Zuhat Urakçı; Teoman Şakalar; Ferit Aslan; Mehmet Uzun; Mustafa Yıldırım; Ahmet Unlu; Derya Kıvrak Salim; Atike Pınar Erdoğan; Elif Sahin; Şeyda Gündüz; Burcu Gülbağcı; Şaziye Burçak Karaca Yayla; Burcu Cakar

Chronic kidney disease and denosumab in metastatic bone disease: A multicenter Turkish cohort study on severe hypocalcemia, skeletal events, and survival

慢性肾病与地诺单抗在骨转移性疾病中的应用：一项关于严重低钙血症、骨骼事件和生存情况的多中心土耳其队列研究

Journal of Bone Oncology

IF3.5

2025-11-210

OAAI

Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study

晚期子宫平滑肌肉瘤中多柔比星–异环磷酰胺与吉西他滨–多西他赛方案的真实世界比较：一项多中心回顾性研究

Discover Oncology

IF2.9

2025-11-170

OAAI

Salih Tunbekici; Gokhan Sahin; Haydar Cagatay Yuksel; Caner Acar; Imge Akın; Hasan Aslanhan; Mert Iscı; Ceren Kabaoglu; Hamit Bal; Abdullah Sakin; Alper Coskun; Mustafa Seyyar; Mehmet Sıddık Dilek; Mahmut Kara; Ali Solmaz; Teyfik Demir; Evrican Zin; Aytac Terzi; Fatih Kus; Ilgın Koc Kus; Zafer Arık; Ali Aytac; Özge Demirkıran; Bilgin Demir; Havva Yesil; Sedat Biter; Tolga Koseci; Ertugrul Bayram; Ahmet Unsal; Ahmet Ozveren; Alper Sevınc; Duygu Ozaskın; Meltem Baykara; Ahmet Unlu; Arıf Kus; Cengiz Karacin; Merih Yalcıner; Galip Can Uyar; Osman Sutcuoglu; Esmanur Kaplan; Teoman Sakalar; Elif Sahin; Gamze Emin; Atilla Yıldırım; Ceren Mordag; Irem ugurlu; Ilhan Hacıbekiroglu; Ibrahim Tunbekici; Pınar Gursoy; Ulus Ali Sanli; Erdem Goker

Neoadjuvant Regimens and Their Impact on Adjuvant T-DM1 Outcomes in HER2-Positive Early Breast Cancer

HER2-Positive早期乳腺癌新辅助治疗方案及其对辅助T-DM1结局的影响

MEDICINA-LITHUANIA

IF2.4

2025-11-010

Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study

多中心真实世界研究：多柔比星–异环磷酰胺方案与吉西他滨–多西他赛方案作为一线疗法治疗晚期非子宫平滑肌肉瘤的疗效与安全性比较

International Journal of Cancer

IF4.7

2025-10-280

PRE

Salih Tunbekici; Gokhan Sahin; Haydar Cagatay Yuksel; Caner Acar; Imge Akın; Hasan Aslanhan; Mert Iscı; Ceren Kabaoglu; Hamit Bal; Abdullah Sakin; Alper Coskun; Mehmet Sıddık Dilek; Mahmut Kara; Ali Solmaz; Evrican Zin; Aytac Terzi; Fatih Kus; Ilgın Koc Kus; Zafer Arık; Ali Aytac; Özge Demirkıran; Bilgin Demir; Havva Yesil; Sedat Biter; Tolga Koseci; Ertugrul Bayram; Ahmet Unsal; Alper Sevınc; Duygu Ozaskın; Meltem Baykara; Ahmet Unlu; Arıf Kus; Cengiz Karacin; Galip Can Uyar; Osman Sutcuoglu; Esmanur Kaplan; Teoman Sakalar; Elif Sahin; Gamze Emin; Atilla Yıldırım; Ceren Mordag; Irem Ugurlu; Ilhan Hacıbekiroglu; Ibrahim Tunbekici; Ulus Ali Sanli; Erdem Goker; Pınar Gursoy

Ertuğrul Bayram

个人简介

教育背景

工作经历

荣誉奖项

研究方向